Hui Feng
Chongqing University(CN)Dalian Medical University(CN)Peking University(CN)Xinyu University(CN)Peking University First Hospital(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Lung Cancer Treatments and Mutations, Zebrafish Biomedical Research Applications, Radiomics and Machine Learning in Medical Imaging
Most-Cited Works
- → A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2(2020)1,483 cited
- → The emerging role and targetability of the TCA cycle in cancer metabolism(2017)550 cited
- → Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial(2022)545 cited
- → Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432(2019)471 cited
- → Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial(2021)392 cited
- → A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy